Clinical Trial Search

Primary: Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6 — -2.5; -3.3 units on a scale — p=0.2966

Primary: Safety of Lithium Carbonate as Measured by Number of Patients in the Safety lead-in Who Experienced a Dose-limiting Toxicity (DLT) — 1 Participants

Primary: 6-month Progression-free Survival Rate (PFS) — 12 participants

Primary: Number of Patients With Late Treatment-related Gastrointestinal (GI) and Genitourinary (GU) Adverse Events (AE) — 12 Participants

Primary: Sensitivity of Regadenoson Stress-MRI for Detection of Coronary Artery Disease (CAD) — 80 Percentage of true positive cases

Primary: Objective Response Rate (ORR) (Phase II) — 0; 5; 14 Participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 97.1; 96.3; 100; 100 percentage of participants

Primary: Maximum Tolerated Dose (MTD) of Vorinostat Given Orally for 10 Days in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With…

Primary: Number of Participants With Imaging Response in Strata 1 and 2 — 0; 1; 1; 0 participants

Primary: Percentage of Composite Responders of at Least 2-Level Improvement of Severity — 20; 3 Participants

Primary: Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL. — 21.0; 28.6 percentage of participants

Primary: Overall Survival — 68 Months

Primary: Progression-Free Survival — 12.9; 12.9 months — p=0.8934

Primary: Progression Free Survival at 12 Weeks — 66; 57.2 percentage of particpants

Primary: Number of Participants With Drug-Related Hypotension — 0 Participants